Harrow, Inc. (HROW), an eyecare pharmaceutical company, Thursday said it hopes to relaunch Triesence, a synthetic corticosteroid approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids, during this year.
The company, which had acquired the U.S. commercial rights to Triesence, said it has manufactured the first of three commercial-scale process performance qualification (PPQ) batches of Triesence. It has also scheduled the second and third required PPQ batches. If these PPQ batches meet specifications, the new Triesence production process will be considered as complete, paving way for Harrow to relaunch during 2024.
Triesence has been on the FDA Drug Shortage List for over five years with all Triesence inventories having been depleted in the U.S. market for over two years, the company said in a release.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.